News

Cerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer

Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft

Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery

Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease

Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada

Cerapedics Announces Canadian Approval of its next-generation bone graft

Canada will be the first commercial market to launch i-FACTOR®+ Matrix

Cerapedics Announces FDA approval of an IDE supplement

The IDE Supplement allows for a reduction in the total number of patients required to be enrolled in the ASPIRE IDE Study on P15-L bone graft in the lumbar spine.

Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery

Data published in The Spine Journal show elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rate with i-FACTOR bone graft compared to allograft

Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data

i-FACTOR® Peptide Enhanced Bone Graft continues to demonstrate statistical superiority to autologous bone in cervical spine surgery

Cerapedics Announces Expansion of Colorado Headquarters

Ortho-biologics company adds 10,000 square feet and doubles employee headcount at Denver metropolitan headquarters